Kyprolis is the trade name for carfilzomib, manufactured by Onyx Pharmaceuticals.
Kyprolis is the trade name for carfilzomib, manufactured by Onyx Pharmaceuticals (Nasdaq: ONXX). It is an anti-cancer drug acting as a selective proteasome inhibitor.
The U.S. Food and Drug Administration (FDA) approved it on 20 July 2012 for use in patients with multiple myeloma who have received at least two prior therapies, including treatment with bortezomib and an immunomodulatory therapy and have demonstrated disease progression on or within 60 days of completion of the last therapy.
Results of phase III confirmatory clinical trial, known as the ASPIRE trial, comparing carfilzomib, lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with relapsed multiple myeloma were presented at an American Society of Hematology meeting in December 2014. They indicated that significantly more patients responded to the three-drug regimen than responded to the two-drug regimen.